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a b s t r a c t 
Objectives: The aim of this study was to review legislative provisions for the reimbursement of biosimi- 
lars, assess the impact of the implemented regulations on access to biosimilars, and to calculate the lost 
opportunity for savings due to the limited availability of biosimilars in Slovakia. 
Methods: The Slovak legislation concerning the reimbursement of biosimilars was reviewed. The reim- 
bursement dossiers of medicines, health technology assessments and appraisals, justification of the reim- 
bursement decisions, final reimbursement decisions and all aspects of the appeal mechanisms are trans- 
parently published on the website of the Slovak Ministry of Health ( http://kategorizacia.mzsr.sk/Lieky ), 
and these were used for this analysis. 
Results: Only 14 reimbursement dossiers were submitted for biosimilars between 2006 and September 
2018 in Slovakia. In 2016 and 2017, no reimbursement dossiers were submitted. The results, based on 
data provided by wholesalers who are legally obliged to deliver information to the State Institute for 
Drug Control, showed that the Slovak health budget could save €28.26- €39.56 million per year if biosim- 
ilars with marketing authorisations were available in the Slovak market, and a 25–35% decrease in price 
compared with that of biological medicinal products. 
Conclusions: Our findings show that proactive strategies and policies should be implemented to increase 
availability and penetration of biosimilars on the Slovak pharmaceutical market to reduce societal losses 
that are caused by the lack of biosimilar medicines availability. 
© 2019 Fellowship of Postgraduate Medicine. Published by Elsevier Ltd. 
This is an open access article under the CC BY-NC-ND license. 






















(  Introduction 
The Constitution of Slovakia guarantees all residents universal
and free access to a wide package of basic health care, covered
by the public health insurance system. All residents are insured
and are obliged to pay premiums to the public health insurance
fund, which is operated by three health insurance companies. The
health-care system in Slovakia is based on universal coverage,
compulsory health insurance, a basic benefits package and a com-
petitive insurance model, with selective contracting of health-care
providers and flexible pricing of health services [1 , 2] . According
to Barnieh et al. the Slovak Republic met the highest standard for∗ Corresponding author. 






2211-8837/© 2019 Fellowship of Postgraduate Medicine. Published by Elsevier Ltd. This is
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) he three criteria deemed important in the process of reimburse-
ent for drugs, which are consideration of the clinical and cost
vidence, full transparency, and the presence of a formal appeal
echanism [3] . 
Slovakia has implemented an internal reference pricing system
or medicines. Based on this system, a maximum price is set
or a standard daily dose of medicine in each specific reference
roup of medicines. All medicines in each internal reference
roup (based on the seven-digit Anatomical Therapeutic Chemical
lassification System code) contain the same active substance(s)
nd are administered in the same form. The reimbursement level
in absolute terms) for a standard daily dose of a medicine with
he particular active substance(s) is linked to the least expensive
lternative in a given internal reference group. A change in a price
f a particular medicine can thus influence the reimbursement of
ther medicines in the same internal reference group. If a biosim-an open access article under the CC BY-NC-ND license. 
































































































































o  lar comes onto the market and into the internal reference group
ontaining a biologic, the reimbursement level of medicines in the
nternal reference group is determined based on the level of the
east expensive alternative in the reference group, which is likely
he biosimilar; the biosimilar is then fully reimbursed by health
nsurance funds in Slovakia. When multiple biosimilars enter the
arket, the same concept is applied and the reimbursement level
s determined based on the level of the least expensive alternative
n the internal reference group. Therefore, the other biosimilars
nd the original biologic are reimbursed at the same reimburse-
ent level (in absolute terms) for the standard daily dose as the
east expensive alternative in the internal reference group [1] . 
The advent of biological medicinal products, i.e., medicines pro-
uced by or extracted from a biological source, has revolutionised
he treatment of many diseases, owing to the specificity of medici-
al products for key disease mediators, e.g. tumour necrosis fac-
or (TNF) alpha, a cytokine involved in the body’s inflammatory
esponse [4] . Biosimilar medicines can provide savings to soci-
ty [5–7] . After marketing authorisation is received from the Eu-
opean Commission, it is the responsibility of member states to
o-ordinate pricing, reimbursement and subsequent entry of these
roducts to the market. This approach contributes to variations in
he use of biosimilars across Europe [8] . 
It has been demonstrated that the lowering of drug costs is
ot just about the use of biosimilars, but also about leveraging the
ompetition to alter the market dynamics between the biosimilar
nd originator product and associated prices [9] . In lower-income
uropean countries with barriers towards the use of patented bi-
logic treatments, the policy objective of biosimilar medicines is
ot only to save money, but to increase patient access to biological
edicines [10] . Many publications only provide a brief overview
f existing policies on biosimilars [11–13] ; therefore, many authors
ave urged that the impact of implemented regulations and prac-
ices are studied in a quantitative manner [11 , 14] . Accordingly, this
rticle provides a review of legislative provisions for the reim-
ursement of biosimilars, the impact of the implemented regula-
ions on the access to biosimilars, and calculations of the lost op-
ortunity for savings due to the limited availability of biosimilars
n Slovakia. 
ethodology 
The authors focused on the impact of implemented regulations
nd practices in a quantitative manner. Comparative analysis was
erformed in three steps: (a) a review of the legislative provi-
ions on biosimilars in Slovakia, (b) comparative analysis of market
hares of biological medicinal products and biosimilars and (c) cal-
ulation of the lost opportunity for savings due to the insufficient
se of biosimilars in Slovakia using two different methods. 
The reimbursement dossiers of medicines, health technology
ssessments and appraisals, justification of reimbursement deci-
ions, final reimbursement decisions and all aspects of appeal
echanisms are transparently published on the website of the
lovak Ministry of Health ( http://kategorizacia.mzsr.sk/Lieky ) and
hese were used for this analysis. The reimbursement decisions
oncerning biosimilars, made by the Slovak Ministry of Health be-
ween 2006 and September 2018, were studied. The consumption
f biosimilars in 2017 in the Slovak Republic was analysed. Sales
ata from wholesalers, which are legally obliged to provide infor-
ation to the State Institute for Drug Control, were used for the
nalysis. The State Institute for Drug Control is the institution of
he state authority in the field of human pharmacy and drug pre-
ursors. 
A control analysis was performed to validate findings. Data from
ealth insurance funds, which are legally obliged to provide in-
ormation to the National Health Information Centre, were used.he National Health Information Centre, a state-funded organisa-
ion founded by the Ministry of Health of the Slovak Republic,
erforms tasks in the area of health statistics and provision of li-
rary and information services in the field of medical sciences and
ealth services. 
esults 
Table 1 shows information about the availability of biosim-
lars in Slovakia in September 2018. It is important to men-
ion that there were 47 biosimilars approved by the European
edicines Agency (EMA) between 2006 and September 2018. In
he same period, only 14 reimbursement dossiers were submitted
or biosimilars in Slovakia. Since 2012, all reimbursement dossiers
or medicines, health technology assessments and appraisals, jus-
ifications of reimbursement decisions, final reimbursement deci-
ions and all aspects of appeal mechanisms have been transpar-
ntly published on the website of the Slovak Ministry of Health.
herefore, in Table 1 we included the exact date of reimbursement
ecisions concerning biosimilars executed by the Slovak Ministry
f Health from 2012 onwards. 
Sales data from wholesalers, which are legally obliged to pro-
ide information to the State Institute for Drug Control, were used
or the analysis of the opportunity cost. The results provided in
able 2 show that the Slovak health budget could save €28.26-
39.56 million per year if biosimilars with marketing authorisa-
ion were available in the Slovak market and a 25–35% decrease
n price (the latter being based on the study by Simon [15] ), com-
ared with that of biological medicinal products (applied as an as-
umption). The second assumption was that there would be no in-
rease in the consumption of particular biosimilars in Slovakia. 
Data from health insurance funds, which are legally obliged
o provide information to the National Health Information Cen-
re, were used for the control analysis. The results provided in
able 3 show that the Slovak health budget could save €25.57-
35.80 million per year if biosimilars with marketing authorisa-
ion were available on the Slovak market and a 25–35% decrease
n price, compared with that of biological medicinal products. It
as assumed that there would be no increase in the consumption
f particular biosimilars in Slovakia. 
Differences between the data from wholesalers of medicinal
roducts and health insurance funds may partly be due to paral-
el export of medicinal products. 
The legislative provisions for biosimilars were reviewed in Slo-
akia. It is important to emphasise that from 2012 to 2017 the
lovak legislature required a 20% initial price reduction for a new
iosimilar compared with the price of the reference biological drug
rom the same reference groups. There were no new biosimilars
oming to the Slovak market in 2016 and 2017. Surprisingly, the
lovak Ministry of Health decided to make entry into the Slo-
ak pharmaceutical market even more difficult for biosimilars. The
ew legislative decision, which came into force on January 1, 2018,
tated that the first biosimilar entering the Slovak market should
ring a 30% initial price reduction compared with the price of
he reference biological drug (for 2019, the first biosimilar com-
ng to the Slovak market should bring a 25% initial price reduction
ompared with that of the reference biological drug). The second
iosimilar coming to the Slovak market should bring an additional
% price reduction compared with that of the first biosimilar, and
he third should bring an additional 5% price reduction compared
ith that of the second biosimilar. Manufacturers of biosimilars
re obliged to decrease prices for the second and third biosimilars
oming to the Slovak market by 5%. 
Moreover, an external reference pricing procedure (requiring an
verage of the three lowest prices for the same medicine available
n pharmaceutical markets across the European Union) is applied
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Table 1 
Availability of biosimilars in Slovakia in September 2018. 
Year of marketing 
authorisation in EMA 
Active substance (name of 
medicinal product) 
Marketing authorisation holder Reimbursement decision of the Slovak 
Ministry of Health 
2006 Somatropin (Omnitrope) Sandoz before 2012 
Comment: Marketing authorisation holder 
withdrawn the medicinal product from 
the reimbursement list 
29.11.2013 
2007 Epoetin alfa (Binocrit) Sandoz before 2012 
2008 Filgrastim (Ratiograstim) Ratiopharm before 2012 
2009 Filgrastim (Zarzio) Sandoz before 2012 
2013 Filgrastim (Grastofil) Apotex 01.04.2014 
2013 Infliximab (Inflectra) Hospira 31.10.2013 
2013 Infliximab (Remsima) Celltrion 31.10.2013 
2014 Insulin glargine (Abasaglar) Eli Lilly/Boehringer Ingelheim 31.03.2015 
2014 Filgrastim (Accofil) Accord Healthcare 28.07.2015 
2014 Follitropin alfa (Bemfola) Finox Biotech 01.10.2015 
2017 Rituximab (Blitzima) Celltrion 10.07.2018 
2017 Rituximab (Rixathon) Sandoz 13.08.2018 
2018 Trastuzumab (Kanjinti) Amgen/Allergan 09.08.2018 
2017 Trastuzumab (Herzuma) Celltrion 13.09.2018 
Table 2 
Estimate of financial savings due to biosimilars, based on data from the State Institute for Drug Control. 
Active substance Financial expenditures 
for ATC5, 2017 ( €) 
Penetration of biosimilars as 
financial expenditures for 
active substances, 2017 ( €) 
Penetration of biosimilars as share of 
financial expenditures of active 
substances /ATC5, 2017 
Estimate of financial saving based on 
25–35% decrease in price (mil. €) 
Adalimumab 34,277,367 0 0% 8.57–12.00 
Bevacizumab 22,280,539 0 0% 5.57–7.80 
Infliximab 16,062,325 3065,672 19.09% 0 
Trastuzumab 12,727,479 0 0% 3.18–4.45 
Rituximab 12,249,874 0 0% 3.06–4.29 
Etanercept 11,743,854 0 0% 2.94–4.11 
Somatropin 8601,234 0 0% 2.15–3.01 
Enoxaparin sodium 8335,371 0 0% 2.08–2.92 
Epoetin 7086,830 4824,873 68.08% 0 
Insulin glargine 5986,612 1353,104 22.6% 0 
Insulin lispro 2173,453 0 0% 0.54–0.76 
Filgrastim 1616,607 1604,009 99.22% 0 
Follitropin alfa 684,997 63,289 9.24% 0 
Teriparatide 639,379 0 0% 0.16–0.22 
Total 144,465,921 10,910,947 7.55% 28.26–39.56 
Table 3 
Estimate of financial savings due to biosimilars, based on data from the National Health Information Centre. 
Active substance Financial expenditures 
for ATC5, 2017 ( €) 
Estimate of financial saving based 
on 25–35% decrease in price (mil. €) 
Adalimumab 36,810,888 9.20–12.88 
Bevacizumab 20,070,324 5.02–7.02 
Trastuzumab 11,670,196 2.92–4.08 
Etanercept 10,887,585 2.72–3.81 
Rituximab 7762,640 1.94–2.72 
Somatropin 7012,162 1.75–2.45 
Enoxaparin sodium 4038,414 1.01–1.41 
Insulin lispro 3209,967 0.54–0.76 
Teriparatide 826,476 0.21–0.29 





















h  as well. There are cases when a 5% decrease in prices for biosim-
ilars would result in a level below even the average of the three
lowest prices of the same medicinal product available on pharma-
ceutical markets across the European Union. Therefore, the prices
of such biosimilars in Slovakia would influence the floor prices
in other European countries using the external reference pricing
system. 
Finally, a problem concerning the new Slovak legislation could
be that new types of packages of biosimilars are considered new
medicinal products, and the concept of the three-step system for
decreasing prices is applied even in this case. For example, when a
biosimilar from a marketing authorisation holder consisting of tennjections is available on the National reimbursement list, and the
arketing authorisation holder would like to include a biosimilar
ith the same active substance consisting of five injections, the
atter is considered a new biosimilar medicine. 
iscussion 
Kutzin argued that the main policy objective of health-care de-
ision makers is to maximise the health gain for the population
y improving the allocative efficiency of limited resources [16] .
he objective of an off-patent drug policy, provided that patients
ave full access to the respective original products prior to their




































































































































i  atent expiry, is usually defined as a reduction in health expendi-
ure without compromising health outcomes [17] . 
Results presented in Table 1 show that Slovakia has a significant
roblem with the availability of biosimilars on the pharmaceutical
arket. There were not available biosimilars in the following ref-
rence groups: epoetin zeta, etanercept, somatropin. 
In Slovakia, all biologic and biosimilar medicines in a given
eference group have the same level of reimbursement from the
ealth insurance funds, which is equal to the price of the least
xpensive alternative in the internal reference group. The copay-
ents for all medicines except the least expensive alternative
qual the difference between the reimbursement level of the least
xpensive alternative and the real prices of medicines in the inter-
al reference group. Therefore, although it is the physician’s deci-
ion to choose the right treatment for a patient, health insurance
unds provide the same reimbursement level (in absolute terms)
or a standard daily dose of biosimilars or the original biologic in
he same internal reference group. Slovakia has a pluralistic sys-
em of health insurance companies, with three health insurance
ompanies operating: the state-owned General Health Insurance
ompany (“Všeobecná zdravotná poist’ov ̌na”) and the private Trust
“Dôvera”) and Union, which covered 60.97%, 29.55%, and 9.47% of
he Slovak population, respectively, in 2019. The cost-saving poten-
ial and the capacity to improve patient access to reimbursed bi-
logics are emphasized as key benefits of increased utilization of
iosimilars by health insurance funds in Slovakia. These health in-
urance funds argue that the same high standards of quality, safety
nd efficacy are applied for biosimilars and original biologics, and
iosimilars have been used safely in the EU since 2006 as alter-
atives to reference medicines. Although health insurance funds
n Slovakia set the reimbursement levels of biosimilars and orig-
nal biologics, they fully accept that the decision regarding which
edicine is the right option for a patient is the responsibility of
hysicians. Prescribers should select the appropriate product based
n sufficient data and knowledge and after informing the pa-
ient of any changes (e.g., original biologic to biosimilar, biosimilar
o original biologic, or biosimilar to biosimilar). Patient access to
igh-cost biological medicines in Slovakia is limited because of the
eed to ensure the sustainability of health care financing in Slo-
akia. There are financing protocols that allow prescriptions only
or subgroups of patients, ensuring reimbursement for second-line
herapy only after the first-line therapy fails, the provision of pre-
criptions for second-line therapy is limited to selected centers. 
The first tender for infliximab (based on the active substance)
as organized by the General Health Insurance Company in 2018.
he winner of the tender was able to decrease the price by 57%
ompared to the official reimbursement level for the standard daily
ose of medicines with the same active substance, which was
inked to the least expensive alternative in the internal reference
roup according to the national reimbursement list. The winner of
he tender volume-based agreement regarding infliximab was not
eclared in the contract with the General Health Insurance Com-
any. After the tender, the marketing authorization holders related
o the rest of the biosimilars (with infliximab as the active sub-
tance) and the original biologic decreased their prices to the same
evel as the winner. Therefore, there were multiple medicines with
nfliximab as the active substance that had a price of 57% lower
han the original reimbursement level for a standard daily dose
f medicine in the internal reference group for infliximab. As the
lovak health insurance funds covered all medicines containing in-
iximab as the active substance at the same reimbursement level
that of the least expensive alternative in the internal reference
roup), the winner of the tender did not increase its market share
f the Slovak pharmaceutical market. 
A second tender was organized by the General Health Insurance
ompany in 2019 for rituximab. However, because the marketinguthorization holders learned from the first tender that there
ould be no volume-based agreement, the winner only offered a
5% lower price compared to the official reimbursement level for
he standard daily dose of medicine in the internal reference group
or rituximab. 
Results presented in Table 2 show that there were low penetra-
ions of biosimilars in the following reference groups: follitropin
lfa, infliximab and insulin glargin. It means that physicians have
lso big influence on the low level of usage of biosimilars. This can
lso lead to low interest of manufacturer to launch new biosimilar
rugs in Slovakia. On the other hand, there were high penetrations
f biosimilars in the following reference groups: epoetin and fil-
rastim. 
Some authors argue that in countries with restricted or no ac-
ess to original biological medicines, the main benefit of biosimi-
ars is not related to their cost-saving potential and the main ob-
ective of biosimilar policies has to be defined from an investment
erspective [18 , 19] by improving patient access via increasing the
umber of treated patients [10 , 20] . However, in Slovakia originals
re available and standardly used for all active substances where
iosimilars are available too. 
Despite the application of rigorous criteria, a potential concern
bout biosimilars is the extrapolation of clinical data required for
egistration to all indications of the original product [21] . 
A systematic literature review found that biosimilar immuno-
enicity differs among active compounds suggesting that immuno-
enicity of anti-drug antibodies should be an important consider-
tion in the treatment decision-making process such as switching
22] . 
Some authors argue that switching from an original biologic
edicine to a biosimilar may induce increased immunogenic re-
ctions [23 , 24] . 
Recent systematic reviews showed, however, that switching pa-
ients from the original chronic biologic therapy to a biosimilar al-
ernative was not associated with increased risk of adverse reac-
ions or loss of efficacy [25 , 26] . 
Still, even with these recent findings, the utilisation of biosimi-
ars, especially for patients on maintenance original biologic treat-
ent, is not an obvious alternative for many physicians [27–30] . 
Some authors argue that information that clinicians deem im-
ortant to assess, such as safety, efficacy and cost, will need to be
rovided before they are comfortable prescribing biosimilars [31] . 
Findings from a recently published systematic review indicate
hat clinicians in Europe and the US do not primarily support the
se of biosimilars as safe and effective therapies in patients already
eceiving originator biological treatment [32] . 
The results of a survey carried out by the European Society for
edical Oncology (ESMO) on biosimilars understanding in oncolo-
ists have highlighted the need for education and worldwide align-
ent [33] . 
The current knowledge and perception among different clini-
ians in Slovakia regarding biosimilars in comparison with original
iologics is unknown. The scarcity of this information in Slovakia
epresents a limitation of our study, which will be alleviated by the
ublication of the results of an ongoing analysis. 
There is no doubt that the evolution of the uptake of biosim-
lars depends on the perception of clinicians, who act as opinion
eaders, as well. In Norway key opinion leaders envisaged first-line
se of biosimilar medicines for biologic naïve patients in inflam-
atory bowel disease [34] . In Denmark, similar approach has been
acilitated by the national council for expensive hospital medicines
n rheumatology and gastroenterology [11 , 35] . The current thinking
f Swedish specialists prescribing TNF α inhibitors seems to be in
ine with the position statement of the Swedish Medical Products
gency, which deems treatment with a biosimilar uncontroversial
n treatment-naïve patients and believes no barriers exist to switch



































































































stable, well-informed patients from the originator biological to the
biosimilar. The position statement also indicates that more data are
needed on multiple switching [9] . 
Clinicians acting as opinion leaders in the European Crohn’s and
Colitis Organisation (ECCO) published that switching from the orig-
inator to a biosimilar in patients with inflammatory bowel disease
is acceptable [36] . Statements such as this can significantly influ-
ence clinicians, who act as opinion leaders, in Slovakia. 
Despite of the underuse of biosimilar medicines, in a recent
legislative amendment Slovakia has increased entry barriers for
biosimilars by requiring significant initial price reductions. At the
same time, Slovakia has reduced the hurdles of including innova-
tive medicines to the reimbursement list. 
Slovakian reimbursement decisions from 2012 to 2017 were
based on thresholds (commonly described with the Greek letter
“λ”) set out in Act No. 363/2011 Z. z that were based on cost and
quality-adjusted life year (QALY). The lower threshold ( λ1) was de-
fined as 24 times average monthly salary (21,192 EUR/QALY), and
the upper threshold ( λ2) was defined as 35 times average monthly
salary (30,905 EUR/QALY). The medicine was reimbursed from the
public health insurance fund (fully or partially) if the incremental
cost was lower or equal to λ1 per QALY. The medicine was con-
ditionally reimbursed if the incremental cost was between the λ1
and λ2 thresholds per QALY. Medicinal products with additional
costs per QALY that exceeded the upper λ2 threshold should not
have been included in the reimbursement list. 
New legislation (updated Act No. 363/2011 Z. z.) came into force
on January 1, 2018, stipulating that reimbursement were to be
based on the following thresholds: 
• the lower threshold ( λ1 ): 35 times average monthly salary (to-
tal 31,920 EUR/QALY); 
• the upper threshold ( λ2 ): 41 times average monthly salary (to-
tal 37,392 EUR/QALY) [37] . 
In general, a medicinal product is reimbursed from the public
health insurance fund (fully or partially) if the incremental cost is
lower or equal to λ1 per incremental QALY. In defined cases, the
thresholds per incremental QALY can be increased up to λ2 . De-
cree No. 93/2018 of the Ministry of Health of the Slovak Republic
sets out the method for determining the impact of a medication
on the public health insurance funds budget, the evaluation crite-
ria for the calculation of the threshold value coefficient, and how
this is calculated [38] . The criteria considered for the threshold in-
crease up to λ2 are as follows: 
• Positive recommendations from agencies responsible for health
technology assessments (HTA) in France, Germany, Scotland,
and England, or the medicinal product is already covered by
health-care funds in France, Germany, Scotland, and England. 
• Availability of other medicinal products with marketing autho-
risations for the same therapeutic indication. 
• The budget impact for 12 months after incorporation of a
medicinal product into the national reimbursement list. 
• The level of incremental QALY brought by a new medicinal
product. 
• Orphan designation given to a medicinal product. 
The HTA agencies included in the legislation are from high-
income countries. It is important to point out that what is cost
effective in these countries, at international price levels, may not
necessarily be cost effective in Slovakia. Van Wilder et al. point
out that the thresholds for incremental costs per QALY introduce a
cost-effectiveness assessment tool for drugs in Slovakia rather than
a reimbursement exclusion regulation [39] . 
Despite higher cost-effectiveness thresholds that give easier
market access to innovative medicines, increased hurdles to marketntry for biosimilars mean that the biologic arena is less compet-
tive and price erosion is minimal. Off-patent biopharmaceuticals
herefore may not be able to deliver the expected savings for the
harmaceutical budget. 
The following proposal, prepared by the Institute of Health Poli-
ies from the Slovak Ministry of Health, to support the biosimilar
olicy in Slovakia is under discussion: 
1. Health insurance funds will define targets for switching from
an original biologic to a biosimilar for each original biologic
with a biosimilar alternative for 3, 12 and 24 months after
a new biosimilar comes onto the market and the criteria for
treatment-naive patients. 
2. Targets will be defined as percentage change from the total
number of patients taking the original biologic based on a par-
ticular indication. 
3. These targets will be included in contracts between health care
providers and health insurance funds. 
4. The Ministry of Health will support the process by issuing a di-
rective to the General Health Insurance Company (state owned)
and the state health care providers. 
5. Financial incentives will be considered to remunerate health
care providers for achievements of the targets. 
onclusions 
We observed that Slovakia has a significant problem with the
vailability and penetration of biosimilars on the pharmaceutical
arket. A national agreement among the Ministry of Health, asso-
iations of health care providers, hospital organizations, the phar-
aceutical industry, and health insurance funds should be reached
n this field. 
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